Scope of this summary
Adults who smoke combustible tobacco, including pregnant persons, in primary and ambulatory care. The current final USPSTF recommendation is dated 2021 and was under update on the source page when checked; current research-plan work must not be mistaken for a new final recommendation. This page does not provide product-specific doses, adolescent treatment, vaping-cessation prescribing, lung-cancer screening criteria or management of acute nicotine poisoning.
The Bottom Line
- Ask every adult about tobacco use, advise cessation clearly and respectfully and offer effective help rather than requiring a declaration of readiness before treatment begins.
- For nonpregnant adults who smoke, USPSTF recommends behavioral intervention plus FDA-approved cessation pharmacotherapy; combining counseling and medication is generally more effective than either alone.
- For pregnant persons, provide behavioral intervention; USPSTF finds evidence insufficient to determine the balance of benefits and harms of cessation pharmacotherapy, requiring individualized obstetric discussion rather than routine extrapolation.
- Do not present electronic cigarettes as an evidence-established cessation intervention under the current USPSTF statement; offer treatments with established effectiveness and address continued combustible and vaping exposure.
Practical clinical workflow
1
Document products, daily pattern, time to first use, prior attempts, withdrawal, triggers, co-use, pregnancy, mental health, substance use, cardiovascular history, medicines and the patient鈥檚 goals and preferences.
2
Give a personalized recommendation to stop, connect the patient to counseling or a quitline and select an FDA-approved option for eligible nonpregnant adults after reviewing contraindications, interactions, adverse effects, access and prior response.
3
ATS strongly recommends varenicline over a nicotine patch for adults initiating controller treatment and recommends offering varenicline rather than waiting when a tobacco-dependent adult is not yet ready to stop; use shared decisions and current labeling.
4
Arrange early and repeated follow-up for adherence, withdrawal, lapses, mood and adverse effects; treat relapse as a reason to revise support and medication rather than as failure or discharge from care.
Safety boundaries and escalation
- Urgently assess severe medication reaction, poisoning, major neuropsychiatric deterioration, suicidality, chest pain or acute neurologic symptoms rather than attributing them automatically to withdrawal.
- Review seizure risk, kidney function, cardiovascular context, pregnancy or lactation and interacting medicines before selecting pharmacotherapy and follow current FDA labeling for dosing and warnings.
- Separate cessation treatment from eligibility for lung-cancer screening and other prevention; stopping smoking does not remove the need to assess cumulative exposure and screening criteria.
- Protect privacy and avoid stigmatizing language, particularly during pregnancy, adolescence or substance-use treatment, because accurate disclosure and sustained engagement are safety interventions.
Localization
USPSTF recommendations are independent expert recommendations, not an official HHS position, and the 2021 statement is visibly marked as being updated. ATS pharmacotherapy guidance is a US society source. State Medicaid formularies, tobacco age law, quitline services and insurer coverage vary.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- U.S. Preventive Services Task ForceTobacco Smoking Cessation in Adults, Including Pregnant Persons: InterventionsFinal Recommendation Statement; update in progress as of 2026-08-20 路 published 2021-01-19 路 accessed 2026-08-20view source
- American Thoracic SocietyInitiating Pharmacologic Treatment in Tobacco-Dependent Adults: An Official ATS Clinical Practice GuidelineDOI 10.1164/rccm.202005-1982ST 路 published 2020-07-15 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.